Investigational drug · Phase 3
N1087
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "N1087"
First trial start
2027
Jan 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "N1087", any sponsor or status.
Conditions studied
As listed on its trial records.
- Female Pattern Hair Loss
- Female Pattern Hair Loss, Androgenic Alopecia
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "N1087" as an intervention, largest first.
- Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.Pivotal-lookingNot yet recruiting
Eurofarma Laboratorios S.A.Industry
NCT07529977 · 372 participants (planned) · Start Jan 31, 2027 · Primary completion Oct 30, 2028
Drug: Minoxidil oral solution; Placebo oral solution · For: Androgenetic Alopecia; Androgenetic Alopecia (AGA)
Sites: Itapevi, Brazil
- Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)Pivotal-lookingNot yet recruiting
Eurofarma Laboratorios S.A.Industry
NCT07303322 · 372 participants (planned) · Start Jan 2027 · Primary completion Jul 2028
Drug: N1087; Placebo · For: Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia
Sites: Itapevi, Brazil
Newest research
PubMed records naming it or its code names, newest first.
- Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT, Shanafelt TD, Leis JF, et al. · Am J Hematol 2017
Also in development for Female Pattern Hair Loss
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.